Cellular vaccine therapies represent an innovative approach to immunization by harnessing the power of the body's own immune cells. These therapies primarily target specific immune cells, such as T-cells and dendritic cells, which play a central role in detecting and responding to pathogens. By genetically modifying or activating these immune cells, cellular vaccines can elicit a more powerful and targeted immune response, offering greater protection against infectious diseases, cancer, and chronic infections. In addition, personalized cellular vaccine strategies are emerging, where a patient's immune system is tailored for optimal effectiveness. Such vaccines have shown promise in oncology, where they aim to stimulate the immune system to target and eliminate cancer cells, as well as in infectious diseases, where they can potentially offer long-lasting immunity. This approach continues to expand with advances in genetic engineering and cellular manipulation, pushing the boundaries of what vaccines can achieve.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey